This genomic-immune axis was clinically validated in KEYNOTE-789 (NCT03515837), where pembrolizumab-chemotherapy failed to improve outcomes in EGFR-mutant NSCLC (Yang et al., 2024a). This evidence concerns the gene EGFR and non-small cell lung carcinoma.